Blog

Current and future therapeutic demands of Tofacitinib

MedAnalytics

Current and future therapeutic demands of Tofacitinib

MedAnalytics defines market demand by measuring the quantity of a generic that required for clinical management for a given time period.It also speculates a market size within the therapeutic class and validates a plan of a product in business consideration based on current and potential market demand. In Q2, 2017 to Q1 2019, Tofacitinib market demand increased at 86.29% CAGR. While demand for others grew: Methotrexate at -3.4% CAGR, Sulfasalazine at -0.26% CAGR, Hydroxychloroquine Sulphate at -9.42% CAGR, Azathioprine at 0.98% CAGR, Cyclosporine at -6.28% CAGR, Chloroquine Phosphate at -17.46% CAGR, Cyclophosphamide at 4.03% CAGR, Mycophenolate at 1.26% CAGR, Apremilast at 15.85% CAGR, Leflunomide at 30.17% CAGR, Rituximab at -3.01% CAGR, Adalimumab at 1.86% CAGR and Tocilizumab at -33.77% CAGR. Over the forecast period of 2020 - 2022, Tofacitinib market demand is expected to increase at 23.74% CAGR. While demand for others are expected to grow: Methotrexate at 0.96% CAGR, Sulfasalazine at 2.2% CAGR, Hydroxychloroquine Sulphate at -1.13% CAGR, Azathioprine at 1.64% CAGR, Cyclosporine at -3.18% CAGR, Chloroquine Phosphate at -23.96% CAGR, Cyclophosphamide at 1.59% CAGR, Mycophenolate at 2.2% CAGR, Apremilast at 9.03% CAGR, Leflunomide at -13.69% CAGR, Rituximab at 3.87% CAGR, Adalimumab at 7.64% CAGR and Tocilizumab at -32.01% CAGR.

Request us for your brand report

Brand report includes - 

  • Present Market share of your brand
  • Current & future performance of your brand
  • Promotional status of your brand
  • Strategic market management of your brand
  • And many more